Optimising proton pump inhibitor therapy in pharmacy
Proton pump inhibitors (PPIs) are a widely used pharmacological treatment option for management of gastro-oesophageal reflux.1

While data on PPIs highlighted concerns about long-term use and the need for appropriate prescribing, an analysis of Pharmaceutical Benefits Scheme (PBS) data following the introduction of prescribing restrictions in 2019 suggests that a reliance on PPIs for management of reflux symptoms remains.2
Indeed, PPIs are an effective and well-tolerated pharmacotherapy for reflux and can be used confidently in the correct indications: first-line as a regular therapy for frequent/severe symptoms of gastro-oesophageal reflux disease (GORD), and second-line as an ‘on-demand’ therapy for mild/intermittent gastro-oesophageal reflux symptoms (see Therapeutic Guidelines for further information).1
THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.


Team PSA 2026: Caroline Diamantis FPS, Prof Mark Naunton MPS and Bridget Totterman MPS[/caption]
A/Prof Fei Sim and Prof Mark Naunton[/caption]

Clinical features
Warm compresses are the cornerstone of treatment, helping to soften the lesion, bring pus to the surface and encourage spontaneous drainage. A clean face cloth soaked in warm (not hot) water should be applied to the closed eyelid for 2–5 minutes, twice daily during the active phase. Once the stye begins to drain, any discharge should be gently wiped away using a clean, warm washcloth. After resolution, continuing warm compresses once daily may help prevent recurrence.2 







